Insider Transactions in Q2 2025 at Reneo Pharmaceuticals, Inc. (RPHM)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 30
2025
|
Edward T Mathers |
BUY
Grant, award, or other acquisition
|
Direct |
4,694
+39.22%
|
-
|
|
Jun 30
2025
|
Isaac Manke |
BUY
Grant, award, or other acquisition
|
Direct |
6,311
+39.22%
|
-
|
|
Jun 23
2025
|
Jason A. Leverone Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
303
-2.29%
|
$606
$2.38 P/Share
|
|
Jun 23
2025
|
Nicholas A Saccomano President and CEO |
SELL
Open market or private sale
|
Direct |
88
-2.39%
|
$176
$2.38 P/Share
|
|
May 15
2025
|
Cormorant Asset Management, LP |
SELL
Open market or private sale
|
Indirect |
1,813,439
-100.0%
|
$1,813,439
$1.85 P/Share
|
|
May 15
2025
|
Acorn Bioventures, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,129,730
+50.0%
|
$1,129,730
$1.85 P/Share
|
|
May 15
2025
|
Acorn Bioventures, L.P. |
BUY
Open market or private purchase
|
Direct |
270,270
+13.65%
|
$270,270
$1.85 P/Share
|
|
May 12
2025
|
Cormorant Asset Management, LP |
SELL
Open market or private sale
|
Indirect |
24,300
-1.32%
|
$24,300
$1.99 P/Share
|
|
Apr 07
2025
|
Jason A. Leverone Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,844
-12.25%
|
$3,688
$2.67 P/Share
|
|
Apr 07
2025
|
Nicholas A Saccomano President and CEO |
SELL
Open market or private sale
|
Direct |
516
-12.29%
|
$1,032
$2.67 P/Share
|
|
Apr 04
2025
|
Jason A. Leverone Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,278
-7.83%
|
$3,834
$3.33 P/Share
|
|
Apr 04
2025
|
Nicholas A Saccomano President and CEO |
SELL
Open market or private sale
|
Direct |
358
-7.86%
|
$1,074
$3.33 P/Share
|